Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV

Jose F Figueroa; Rebekah I Stein; Jessica Phelan; E John Orav; Grace Luu; Shibani S Mukerji; Emily P Hyle

doi:10.1001/jamanetworkopen.2026.18029

Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV

JAMA Netw Open. 2026 Jun 1;9(6):e2618029. doi: 10.1001/jamanetworkopen.2026.18029.

Authors

Jose F Figueroa^{1

2

3}, Rebekah I Stein¹, Jessica Phelan¹, E John Orav^{2

3}, Grace Luu³, Shibani S Mukerji^{3

4}, Emily P Hyle^{3

5

6}

Affiliations

¹ Department of Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
² Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Department of Neurology, Massachusetts General Hospital, Boston.
⁵ Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston.
⁶ Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston.

No abstract available

Plain language summary

This cross-sectional study examines the use of long-acting injectable antiretroviral therapy among Medicare beneficiaries with HIV and characterizes the differences between people receiving oral antiretroviral therapy vs long-acting injectable antiretroviral therapy.